🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Negative results from STAMPEDE arm A and K, presented by silke gillessen. No benefit from adding metforlin to SoC in mHSPC. HR=0.91., p=0.14. OncoAlert

ARANOTE - let s add one more ( are we at 20 now ? ) in a series of ALL positive trials showcasing the nodal role of androgen signaling inhibition . Arun Azad the survival fu is way too short and enriched for the super aggressive subset that will progress right through .. let

#ESMO24 recap is here! 📺 Important data, expert opinions – all available now on #high5oncologyTV. Free & on demand! high5oncology.tv/meeting-covera… #Oncology #ESMO2024 #MedicalUpdates Evandro de Azambuja, MD, PhD Eva M Ciruelos Javier Cortes MD PhD Carmen Criscitiello G Curigliano MD PhD Rebecca Dent AGO Breast Study Group

To wrap up the prostate cancer series at #ESMO24, Eleni Efstathiou and colleagues share insights on everything from ARANOTE to Contact-02 in the final roundtable coverage. mashupmd.com/expert-collect…

A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇👇👇👇👇👇👇👇 sciencedirect.com/science/articl… The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in

A lot was covered in prostate cancer at #GU25, including two studies on TALAPRO-2 and the meta-analysis of STOPCAP. GU Oncology Now has been at the helm of coverage, sharing numerous updates in prostate cancer. 📖Read more from Eleni Efstathiou: mashupmd.com/expert-collect…

💡 ASCO GU 2025: What’s Next for Prostate Cancer Treatment? Major studies. Expert opinions. Clinical relevance. high5oncologyTV delivers: ✔ 100-Second Key Takeaways – fast, focused, and evidence-based. ✔ Deep-Dive Panels on the most practice-changing prostate cancer data. ✔

ASCO #GU25 may be over, but groundbreaking prostate cancer research continues. Explore discussions on Lu-PSMA-617 in mCRPC & final TALAPRO-2 analysis showing survival benefits with talazoparib + enzalutamide. Check out more from Eleni Efstathiou! mashupmd.com/expert-collect…

In her final post-ASCO #GU25 newsletter, Eleni Efstathiou reflects on key prostate cancer research. Explore essential ASCO GU findings and recaps of studies like STOPCAP, TALAPRO-2, and Lu-PSMA-617. Learn more! mashupmd.com/expert-collect…

Join us and the #ProstateCancer Experts Drs. Shore, Eleni Efstathiou, Stephen Freedland, MD and ZERO Prostate Cancer for Dinner on Sunday, April 27, 2025 during the #AUA25 Annual Meeting. Register Today to Join Us Live in Las Vegas or Online! bit.ly/PT25-T #AUA2025

Fundamentally Hellenic 🇬🇷 Hellas remains through the eons a state of mind. Here s to a starry eyed girl with a happy old soul #Klavdia !!

#ASCO2025 #prostatecancer OncoAlert IronMan registry use to confirm the prognostic value of an undetectable psa when on treatment for mHSPC Kudos for the ensuing SWOG trial led by Drs Sokolova OHSU Knight Cancer Institute and Ong to fine tune the use of docetaxel in mHSPC

#ASCO2025 #prostatecancer #ASCO25 OncoAlert Stampede : 🎁 that keeps giving . Is PTEN loss plus high decipher finding a first spot as a predictor to docetaxel response ? Put that in context with mHSPC data on DDR mutational status and ANSWER : Early genomic testing is here 😎

PARP inhibition for HRR deficient mCSPC is here !! Niraparib plus Abi show clear benefit in rPFS and secondary OS trending in the right direction ! The Time or EARLY systematic genomic testing is here 🙌🏻 #ASCO25 OncoAlert

Presented at #ASCO25 Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive #ProstateCancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes meetings.asco.org/abstracts-pres… The

I love to learn from these discussions 🙏🏻